NovaBridge Biosciences (NBP)

Every figure this model derived for NBP, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2023-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 210,842,000 CashAndCashEquivalentsAtCarryingValue 2025-12-31
current assets 217,520,000 AssetsCurrent 2025-12-31
current liabilities 26,894,000 LiabilitiesCurrent 2025-12-31
equity 230,941,000 StockholdersEquity 2025-12-31
interest expense 102,000 InterestExpense 2023-12-31
revenue 632,000 Revenues 2023-12-31
sbc 0 ShareBasedCompensation 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up NBP on one particular measure came for.

RatioValue
current ratio8.18
current ratio reported8.09
deferred revenue growth-75.36
growth cv1.89
revenue growth-140.75
revenue growth per share-140.75
sbc pct revenue0.0

What to be careful about

What this model itself distrusts about NBP's figures. Written by the derivation as it ran, not added afterwards.